FYERS
Transgene Biotek2.75
+0.02 (+0.73%)

Transgene Biotek Share Price

2.75+0.02 (+0.73%)
-28.39% past 1 Year

Corporate filings & documents

Announcements

Newspaper Publication
1 month ago
Newspaper Publication
1 month ago
Unaudited Financial Results for the quarter ended 30th June 2026.
1 month ago
Unaudited Financial Results for the quarter ended 30th June 2026.
1 month ago
Sub: Outcome of the Meeting of the Board of Directors held on August 07 2026.This has reference to our letter dated 22nd July 2026 Intimating the meeting of the Board of Directors of the Company.At a meeting of the Board of Directors of the company held on 07th August 2026 the following decisions have been taken:1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2025-26 subject to obtaining the necessary approval from the Registrar of Companies wherever applicable.
1 month ago
Sub: Outcome of the Meeting of the Board of Directors held on August 07 2026.This has reference to our letter dated 22nd July 2026 Intimating the meeting of the Board of Directors of the Company.At a meeting of the Board of Directors of the company held on 07th August 2026 the following decisions have been taken:1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2025-26 subject to obtaining the necessary approval from the Registrar of Companies wherever applicable.
1 month ago
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby infom you that a meeting of the Board of Directors of Transgene Biotek Limited is scheduled to be held on Friday August 07 2026 inter alia to consider and approve the following matters: 1. To consider and approve the n-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30 2026.2. To consider and approve the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30h June 2026.3. To consider and approve seeking an extension of time for holding the Annual General Meeting (AGM) of the Company for the Financial Year 2025-26.4. To consider and approve the appointment of the internal auditor of the Company for financial year 2026-27.5. To transact such other business as may be required.
2 months ago
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby infom you that a meeting of the Board of Directors of Transgene Biotek Limited is scheduled to be held on Friday August 07 2026 inter alia to consider and approve the following matters: 1. To consider and approve the n-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30 2026.2. To consider and approve the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30h June 2026.3. To consider and approve seeking an extension of time for holding the Annual General Meeting (AGM) of the Company for the Financial Year 2025-26.4. To consider and approve the appointment of the internal auditor of the Company for financial year 2026-27.5. To transact such other business as may be required.
2 months ago
Compliance - 57(4)
2 months ago
Compliance - 57(4)
2 months ago
Statement of Deviation & Variation
2 months ago
Statement of Deviation & Variation
2 months ago
Compliance -57 (5)
2 months ago
Compliance -57 (5)
2 months ago
Compliances - Certificate under Reg. 74(5) of SEBI
2 months ago
Compliances - Certificate under Reg. 74(5) of SEBI
2 months ago
Closure of Trading Window
3 months ago
Closure of Trading Window
3 months ago
Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.
3 months ago
Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.
3 months ago
Audited Financial Results
3 months ago
Audited Financial Results
3 months ago
This has reference to our letter dated May 13 2026 The Board of Directors of the Company at their meeting held on May 29 2026 have resolved as follows:Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose herewith the following: a) Audited Financial Results (Standalone and Consolidated) of the Company for the fourth quarter and financial year ended March 31 2026. b) Report of the Auditors on the Audited Financial Results both for (Standalone and Consolidated) financial statements for the financial year ended March 31 2026. c) Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for Consolidated and Standalone Financial Statements for the Financial Year ended March 31 2026.The meeting of the Board of Directors of the Company commenced at 11.00 AM and concluded at 11.30 AM.We kindly request you to take the above said on record.
3 months ago
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve To Consider and approve the Audited Financial Results (Standalone and consolidated) of the Company for the fourth quarter and financial year ended March 31 2026.
4 months ago
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve To Consider and approve the Audited Financial Results (Standalone and consolidated) of the Company for the fourth quarter and financial year ended March 31 2026.
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPLIANCE OFFICER AND COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPLIANCE OFFICER AND COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months ago
Non-Applicability of Regulation 32(1) of SEBI.
5 months ago
Compliance - 57 (4)
5 months ago
Non-Applicability of Reg -57 (5) of SEBI LODR Regulations 2015.
5 months ago
Non-Applicability of Reg -57 (5) of SEBI LODR Regulations 2015.
5 months ago
Compliance certificate 7(3)
5 months ago
Compliance certificate 7(3)
5 months ago
Compliances Certificate under 74 (5) of SEBI
5 months ago
Compliances Certificate under 74 (5) of SEBI
5 months ago
Closure of Trading Window
6 months ago
Newspaper Publication
7 months ago
Newspaper Publication
7 months ago
Dear Sir/Madam This has reference to our letter dated January 28 2026.1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company for the Quarter ended 31.12.2025 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2025 has also been approved.The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.
7 months ago
Dear Sir/Madam This has reference to our letter dated January 28 2026.1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company for the Quarter ended 31.12.2025 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2025 has also been approved.The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.
7 months ago
General Announcements
7 months ago
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 31st December 2025.2) To consider and approve the Limited Review Report (Standalone & Consolidated) for the quarter ended 31st December 2025.3) To transact such other business as may be required.
7 months ago
Statement of Deviation & Variation
8 months ago
Compliance -57 (5)
8 months ago
Compliance -57 (4)
8 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 12/01/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
8 months ago
Compliances -Certificate under Reg.74(5) of SEBI.
8 months ago
OUT COME RESULTS AND SCRUTINIZER REPORTS
8 months ago
OUT COME OF VOTING AT 35TH AGM
8 months ago
Outcome of 35th AGM
8 months ago

Annual reports

FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Empty box

No presentations found

Transgene Biotek Ltd Share Price Today

The Transgene Biotek Ltd share price today is ₹2.75. During the trading session, the Transgene Biotek Ltd share price opened at ₹2.75 and recorded an intraday high of ₹2.79 and a low of ₹2.72. Last closing price was ₹2.72. Over the past 52 weeks, the Transgene Biotek Ltd share price has ranged between ₹1.83 and ₹4.50. The current Transgene Biotek Ltd stock price reflects real-time market activity based on executed trades on the exchange.